Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2060]

The evolving treatment landscape in immune thrombocytopenia

Dr Hanny Al-Samkari - Massachusetts General Hospital, Boston, USA

The evolving treatment landscape in immune thrombocytopenia ( Dr Hanny Al-Samkari - Massachusetts General Hospital, Boston, USA )

First-in-class switchable allogeneic CAR-T therapy shows promising activity in...

Prof Martin Wermke - National Center for Tumor Diseases, Dresden, Germany

$First-in-class switchable allogeneic CAR-T therapy shows promising activity in relapsed or refractory AML ( Prof Martin Wermke - National Center for Tumor Diseases, Dresden, Germany )$

Epcoritamab plus rituximab and lenalidomide improves outcomes across follicular...

Dr Benoit Tessoulin - CHU de Nantes, Nantes, France

Epcoritamab plus rituximab and lenalidomide improves outcomes across follicular lymphoma subgroups ( Dr Benoit Tessoulin - CHU de Nantes, Nantes, France )

Epcoritamab improves progression-free survival in relapsed or refractory large...

Prof Christopher Fox - University of Nottingham, Nottingham, UK

$Epcoritamab improves progression-free survival in relapsed or refractory large B-cell lymphoma ( Prof Christopher Fox - University of Nottingham, Nottingham, UK )$

Mezigdomide plus carfilzomib dexamethasone improves PFS in R/R multiple myeloma

Prof Meletios Dimopoulos - National and Kapodistrian University of Athens...

Mezigdomide plus carfilzomib dexamethasone improves PFS in R/R multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )

Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1...

Dr Chiara Sartor - University of Bologna, Bologna, Italy

Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1 mutated AML with molecular failure ( Dr Chiara Sartor - University of Bologna, Bologna, Italy )

DVRd improves MRD negativity and PFS in transplant ineligible newly diagnosed...

Dr Saad Usmani - Memorial Sloan Kettering Cancer Center, New York City, USA

DVRd improves MRD negativity and PFS in transplant ineligible newly diagnosed multiple myeloma ( Dr Saad Usmani - Memorial Sloan Kettering Cancer Center, New York City, USA )

Favezelimab plus pembrolizumab improves progression-free survival in PD-1...

Dr Guilherme Perini - Hospital Israelita Albert Einstein, São Paulo, Brazil

$Favezelimab plus pembrolizumab improves progression-free survival in PD-1-refractory classic Hodgkin lymphoma ( Dr Guilherme Perini - Hospital Israelita Albert Einstein, São Paulo, Brazil )$

First-in-human study of in vivo CAR-T therapy shows promising activity in...

Dr Ying Huang - CEO, Legend Biotech

$First-in-human study of in vivo CAR-T therapy shows promising activity in relapsed or refractory B-cell non-Hodgkin lymphoma ( Dr Ying Huang - CEO, Legend Biotech )$

Anselamimab reduces mortality and cardiovascular hospitalisation in kappa light...

Prof Ashutosh Wechalekar - University College London Hospitals, London, UK

Anselamimab reduces mortality and cardiovascular hospitalisation in kappa light chain AL amyloidosis ( Prof Ashutosh Wechalekar - University College London Hospitals, London, UK )

CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R...

Prof Liang Wang - Beijing Tongren Hospital, Beijing, China

CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R large B cell lymphoma ( Prof Liang Wang - Beijing Tongren Hospital, Beijing, China )

Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute...

Prof Elias Jabbour - The University of Texas MD Anderson Cancer Center, Houston...

Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia ( Prof Elias Jabbour - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer